Keros Therapeutics (KROS) Financial Statements & Analysis

Keros Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Keros Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	244.06	3.55	0.15	0.00	20.10	0.00	10.00	10.00
Cost of Revenue	127.14	0.00	0.00	0.00	55.14	33.86	17.35	10.11
Gross Profit	244.06	3.55	0.15	0.00	20.10	-33.86	-7.35	-0.11
Operating Expenses
Research & Development	129.64	173.63	135.26	87.27	55.14	33.86	17.38	10.11
Selling, General & Administrative	46.85	40.75	34.83	27.53	21.33	12.80	3.18	1.58
Operating Expenses	176.49	213.15	170.09	114.79	76.47	12.80	20.01	11.32
Operating Income	67.57	-209.60	-169.94	-114.79	-56.37	-46.66	-10.56	-1.69
Other Income/Expense
Interest Income	24.87	0.00	0.00	0.00	0.03	0.01	0.00	0.01
Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.01	0.01	0.00
Other Income/Expense	24.33	22.54	16.95	10.11	-0.36	1.13	-1.77	0.61
Income
Income Before Tax	91.90	-187.05	-152.99	-104.68	-56.73	-45.53	-12.34	-1.08
Income Tax Expense	4.88	0.30	0.00	0.00	-2.01	-0.17	0.00	0.26
Net Income	87.01	-187.35	-152.99	-104.68	-58.74	-45.36	-12.34	-1.34
Net Income - Continuous Operations	87.01	-187.35	-152.99	-104.68	-58.74	-45.36	-12.34	-1.34
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-
EBITDA	69.08	-208.37	-152.18	-104.00	-56.00	-46.38	-11.89	-0.77
EBIT	67.57	-209.60	-152.99	-104.68	-56.37	-46.66	-	-
Depreciation & Amortization	1.51	1.23	0.82	0.67	0.38	0.28	0.44	0.30
Earnings Per Share
Basic EPS	2.00	-5.00	-5.00	-4.00	-3.00	-3.00	-1.00	-
Diluted EPS	2.00	-5.00	-5.00	-4.00	-3.00	-3.00	-1.00	-
Basic Shares Outstanding	37.22	37.44	29.45	25.24	23.33	15.51	8.88	8.88
Diluted Shares Outstanding	37.86	37.44	29.45	25.24	23.33	15.51	8.88	8.88

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Keros Therapeutics Financial Statements

What was Keros Therapeutics's revenue in fiscal 2025?

Keros Therapeutics reported revenue of $244.06M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 6775.0% from $3.55M a year earlier.

Is Keros Therapeutics profitable?

Yes. Keros Therapeutics earned net income of $87.01M in fiscal 2025, a net margin of 35.7%. In fiscal 2024 it lost $187.35M.

What is Keros Therapeutics's operating margin?

Keros Therapeutics's operating income was $67.57M on revenue of $244.06M in fiscal 2025, an operating margin of 27.7%, compared with -5904.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition